

09/857115

JC18 REC'd PCT/PTO 01 JUN 2001

PCT/GB99/04045

WO 00/32218

## SEQUENCE LISTING

### (1) GENERAL INFORMATION:

#### (i) APPLICANT:

- (A) NAME: FERRING BV
- (B) STREET: MARSSTRAAT 9, PO BOX 3129
- (C) CITY: HOOFFDORP
- (D) STATE: NONE
- (E) COUNTRY: THE NETHERLANDS
- (F) POSTAL CODE (ZIP): 2130 KC

#### (ii) TITLE OF INVENTION: CONTROLLED RELEASE FORMULATION

#### (iii) NUMBER OF SEQUENCES: 7

#### (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

### (2) INFORMATION FOR SEQ ID NO: 1:

#### (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

#### (ii) MOLECULE TYPE: cDNA

#### (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CTGCAGCTGC CTGAAGGAG

19

### (2) INFORMATION FOR SEQ ID NO: 2:

#### (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GGGCGGGGCG GGGCTCTCG

19

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

ATTCTACTGA CTTGGTGCGT G

21

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GGAATATGTG CAACTTGGTG T

21

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "Glu in first position is pyroGLU"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Glu His Trp Ser Tyr Gly Leu Arg Pro Gly  
1            5            10

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "Glu in first position is pyroGlu"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Glu His Trp Ser His Gly Trp Tyr Pro Gly  
1            5            10

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:1
- (D) OTHER INFORMATION:/product= "Glu is pyroGlu"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:5
- (D) OTHER INFORMATION:/product= "Xaa is His or Tyr"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:7
- (D) OTHER INFORMATION:/product= "Xaa is Trp or Leu"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:8
- (D) OTHER INFORMATION:/product= "Xaa is Tyr or Arg"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Glu His Trp Ser Xaa Gly Xaa Xaa Pro Gly  
1            5            10

RECEIVED 26 DEC 2001

1

SEQUENCE LISTING

<110> QI, STEVE  
AKINSANYA, KAREN  
HAYWARD, AMANDA

<120> CONTROLLED RELEASE FORMULATION COMPRISING GNRH-II

<130> 033236/0115

<140> 09/857,115

<141> 2001-06-01

<150> PCT/GB99/04045

<151> 1999-02-12

<150> GB 9826662.0

<151> 1998-12-03

<160> 7

<170> PatentIn Ver. 2.1

<210> 1

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 1

ctgcagctgc ctgaaggac

19

<210> 2

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 2

gggcggggcg gggctctcg

19

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 3

attctactga cttggtgcgt g

21

RECEIVED 26 DEC 2001

<220>  
<223> Description of Artificial Sequence: Primer

21

```
<220>
<223> Description of Artificial Sequence: Synthetic
      Peptide
```

```
<220>  
<221> MOD_RES  
<222> (10)  
<223> C-Term Amidated
```

```
<210> 6
<211> 10
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence: Synthetic
      Peptide
```

```
<220>  
<221> MOD_RES  
<222> (1)  
<223> pyroGlu
```

```
<220>  
<221> MOD_RES  
<222> (10)  
<223> C-Term amidated
```

[illegible]

<400> 6  
 Glu His Trp Ser His Gly Trp Tyr Pro Gly  
       1                      5                      10

<210> 7  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
       Peptide

<220>  
 <221> MOD\_RES  
 <222> (1)  
 <223> pyroGlu

<220>  
 <221> MOD\_RES  
 <222> (5)  
 <223> His or Tyr

<220>  
 <221> MOD\_RES  
 <222> (7)  
 <223> Trp or Leu

<220>  
 <221> MOD\_RES  
 <222> (8)  
 <223> Tyr or Arg

<220>  
 <221> MOD\_RES  
 <222> (10)  
 <223> C-Term Amidated

<220>  
 <223> provided that when Xaa at position (5) is Tyr and  
       Xaa at position (7) is Leu, then Xaa at position (8)  
       is not Arg.

<400> 7  
 Glu His Trp Ser Xaa Gly Xaa Xaa Pro Gly  
       1                      5                      10